BRCA1 and BRCA2 are two of the most important genes in inherited cancer predisposition. They are probably the most sequenced and characterised genes in clinical medicine, but many unanswered questions remain. This presentation will provide an overview of these genes from their discovery in the mid 90s to the current day. It will focus on the known cancer predisposition spectrum, cancer risk estimates, the development of mainstream testing and current controversies in the management of individuals who carry pathogenic variants in these genes.